中国实用眼科杂志
中國實用眼科雜誌
중국실용안과잡지
Chinese Journal of Practical Ophthalmology
2015年
7期
748-751
,共4页
特发性脉络膜新生血管%Ranibizumab%脉络膜厚度
特髮性脈絡膜新生血管%Ranibizumab%脈絡膜厚度
특발성맥락막신생혈관%Ranibizumab%맥락막후도
Idiopathic choroidal neovascularization%Ranibizumab%subfoveal choroidal thickness
目的 探讨玻璃体腔注射Ranibizumab后特发性脉络膜新生血管(ICNV)的视网膜和脉络膜厚度的变化.方法 回顾性临床病例系列研究.对2012年1月至2013年10月在潍坊医学院附属医院眼科确诊为ICNV的患者36例(36只眼)的临床资料进行回顾性研究,玻璃体腔注射Ranibizumab,观察注射前及注射后的BCVA、CFT、SFCT及FFA结果,随访6～12个月.采用配对资料的t检验进行统计学分析.结果 注射前BCVA (0.512±0.245) logMAR,注射后(0.324±0.278) logMAR,差异有统计学意义(t =3.0441,P＜0.01).注射前CFT (356.45±89.26)μm,注射后(219.46±67.39)μm,差异有统计学意义(t =7.3491,P＜0.01).注射前SFCT (217.47±59.34) μm,未受累对侧眼(279.59±73.26)μm,相比具有统计学意义(t=3.9534,P=0.0002),注射后至随访终点SFCT (238.26±64.91) μm,注射前后相比无统计学意义(t=1.4184,P=0.1605).FFA检查结果显示总有效率为88.89％.结论 玻璃体腔注射Ranibizumab可以使ICNV获得显著的视力改善,黄斑中心凹下脉络膜厚度减少,可能和ICNV的病理生理改变有关,但玻璃体腔注射Ranibizumab后对ICNV脉络膜厚度影响不大.
目的 探討玻璃體腔註射Ranibizumab後特髮性脈絡膜新生血管(ICNV)的視網膜和脈絡膜厚度的變化.方法 迴顧性臨床病例繫列研究.對2012年1月至2013年10月在濰坊醫學院附屬醫院眼科確診為ICNV的患者36例(36隻眼)的臨床資料進行迴顧性研究,玻璃體腔註射Ranibizumab,觀察註射前及註射後的BCVA、CFT、SFCT及FFA結果,隨訪6～12箇月.採用配對資料的t檢驗進行統計學分析.結果 註射前BCVA (0.512±0.245) logMAR,註射後(0.324±0.278) logMAR,差異有統計學意義(t =3.0441,P＜0.01).註射前CFT (356.45±89.26)μm,註射後(219.46±67.39)μm,差異有統計學意義(t =7.3491,P＜0.01).註射前SFCT (217.47±59.34) μm,未受纍對側眼(279.59±73.26)μm,相比具有統計學意義(t=3.9534,P=0.0002),註射後至隨訪終點SFCT (238.26±64.91) μm,註射前後相比無統計學意義(t=1.4184,P=0.1605).FFA檢查結果顯示總有效率為88.89％.結論 玻璃體腔註射Ranibizumab可以使ICNV穫得顯著的視力改善,黃斑中心凹下脈絡膜厚度減少,可能和ICNV的病理生理改變有關,但玻璃體腔註射Ranibizumab後對ICNV脈絡膜厚度影響不大.
목적 탐토파리체강주사Ranibizumab후특발성맥락막신생혈관(ICNV)적시망막화맥락막후도적변화.방법 회고성림상병례계렬연구.대2012년1월지2013년10월재유방의학원부속의원안과학진위ICNV적환자36례(36지안)적림상자료진행회고성연구,파리체강주사Ranibizumab,관찰주사전급주사후적BCVA、CFT、SFCT급FFA결과,수방6～12개월.채용배대자료적t검험진행통계학분석.결과 주사전BCVA (0.512±0.245) logMAR,주사후(0.324±0.278) logMAR,차이유통계학의의(t =3.0441,P＜0.01).주사전CFT (356.45±89.26)μm,주사후(219.46±67.39)μm,차이유통계학의의(t =7.3491,P＜0.01).주사전SFCT (217.47±59.34) μm,미수루대측안(279.59±73.26)μm,상비구유통계학의의(t=3.9534,P=0.0002),주사후지수방종점SFCT (238.26±64.91) μm,주사전후상비무통계학의의(t=1.4184,P=0.1605).FFA검사결과현시총유효솔위88.89％.결론 파리체강주사Ranibizumab가이사ICNV획득현저적시력개선,황반중심요하맥락막후도감소,가능화ICNV적병리생리개변유관,단파리체강주사Ranibizumab후대ICNV맥락막후도영향불대.
Objective To study the change of subfoveal choroidal thickness after intravitreal ranibizumab for idiopathic choroidal neovascularization.Methods The case series study included 36 patients with ICNV.All eyes with ICNV were treated with an intravitreal injection of 0.5 mg ranibizumab.Subfoveal choroidal thickness was measured using enhanced depth imaging optical coherence tomography.Best-corrected visual acuity and central foveal thickness were measured in presentation and final visit.All patients were followed up within 6-12 months.Results Mean logarithm of the minimum angle of resolution best-corrected visual acuity improved from 0.512±0.245 initially to 0.324±0.278 after treatment (P ＜0.01).Mean central subfield thickness decreased from 356.45±89.26 μ m at baseline to 219.46±67.39 μm after treatment (P ＜0.01).The subfoveal choroidal thickness was significantly thinner in eyes with idiopathic CNV (217.47±59.34 μm) than in the unaffected fellow eyes (279.59±73.26 μm,P ＜0.01).Conclusions Subfoveal choroidal thickness is reduced and may be associated with the pathophysiology of idiopathic CNV.Intravitreal bevacizumab result in significant visual and anatomical improvement in patients with idiopathic CNV.
